Search
Triflusal
go.drugbank.com/drugs/DB08814ApprovedWithdrawnThe latest translates into the expansion of peripheral blood vessels.[A31675] It is very important as a secondary prevention of ischemic stroke by offering a lower risk of bleeding. … Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative.
Brilliant blue G
go.drugbank.com/drugs/DB15594ApprovedBrilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830] … Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures.
Categories: Compounds used in a research, industrial, or household settingPemivibart
go.drugbank.com/drugs/DB18720Investigational[L51733] Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.[L51728] … [L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.
Fluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalAs of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. … Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients.
Categories: Metabolic Side Effects of Drugs and Substances, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCarglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalCarglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. … Food and Drug Administration (FDA) on 18 March 2010.
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant] … [A189195] The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSacubitril
go.drugbank.com/drugs/DB09292ApprovedInvestigationalInhibition of neprilysin therefore leads to reduced breakdown and increased concentration of endogenous natriuretic peptides in addition to increased levels of vasoconstricting hormones such as angiotensin … Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalMaraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the … It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
Fedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigational[A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090] … Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.
Categories: combinations of sulfonamidesAntihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalPEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein. … with at least one molecule of polyethylene glycol (MW 20 kDa) [FDA label].
Categories: Compounds used in a research, industrial, or household settingProducts: ADYNOVATE 500®IU / VIAL, ADYNOVATE 3000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION